This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

CHANTIX® (varenicline) Demonstrates Efficacy In Smokers Who Previously Attempted To Quit Smoking With CHANTIX

Pfizer Inc. (NYSE: PFE) announced today that a post-marketing study assessing the efficacy and safety of varenicline (CHANTIX ®/CHAMPIX ®) in a population of smokers who had made a previous attempt to quit smoking with CHANTIX, and either did not succeed in quitting or relapsed after treatment, met its primary endpoint.

CHANTIX significantly increased continuous abstinence rates compared to placebo at weeks nine to 12, the last four weeks of treatment (primary endpoint). The efficacy rates were consistent with findings seen in other CHANTIX clinical trials in smokers who had not been previously treated with CHANTIX. The safety and tolerability profile of CHANTIX in this study was also consistent with previous studies. The most commonly reported treatment-emergent adverse events were nausea, abnormal dreams and headache, with incidence rates similar to previous CHANTIX studies.

“Smoking is considered a chronic, relapsing medical condition. The availability of pharmacological treatments has led to a large and growing population of smokers who have made previous quit attempts but were ultimately unsuccessful,” said Steven J. Romano, M.D., senior vice president and medicines development group head, Primary Care Business Unit, Pfizer Inc. “These new data show that, for some adult smokers who had previously taken CHANTIX but either did not quit smoking or relapsed after quitting, another quit attempt with CHANTIX may be fruitful.”

Study Background

This study was a Phase 4, 12-week, randomized, double-blind, placebo-controlled, multi-center study, which evaluated the efficacy and safety of varenicline tartrate 1 mg BID for smoking cessation in adult subjects, who had made a previous attempt to quit smoking with CHANTIX and either did not succeed in quitting or relapsed after treatment. Patients included in this study had taken CHANTIX for a smoking-cessation attempt in the past (for a total treatment duration of a minimum of two weeks), and at least three months prior to study entry, and had been smoking for at least four weeks.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs